{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:37:06Z","timestamp":1766504226900},"reference-count":82,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>Immune checkpoint inhibitors present clinicians with both an exciting step forward in cancer treatment and the unknown possibilities of an unshackled immune system. The latter phenomena, known as immune-related adverse events (irAEs), are of particular interest because they may affect any organ system with autoimmune-like pathologies, such as hepatitis and colitis. Within the cardiovascular system, irAEs associated with immune checkpoint blockade exist as a broad clinical spectrum, with autoimmune myocarditis being the best-characterized entity at this time. In general, irAEs are often reversible with immunosuppression. However, irAEs that affect the cardiovascular system pose the possibility of a rapid and fatal clinical deterioration. The mortality attributed to immune checkpoint blockade-associated autoimmune myocarditis, as reported in the WHO database, exists from 36% to 67%, dependent on the therapeutic regimen. Yet, despite the potential severity such events pose, guidelines dictating the identification of immune checkpoint inhibition irAEs do not exist, providing a stark contrast with other anticancer medications with known cardiovascular effects. The lack of guidelines may be related to the perceived rarity of these events, yet a recent study of immune checkpoint inhibition-associated autoimmune myocarditis suggests that this clinical entity may be more prevalent than initially believed. Until more standardized information regarding these potentially serious events is available, the study of documented cases is instructive to improve identification of such phenomena, as well as the outcomes for patients who develop them.<\/jats:p>","DOI":"10.1097\/crd.0000000000000217","type":"journal-article","created":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T21:16:10Z","timestamp":1529097370000},"page":"97-107","source":"Crossref","is-referenced-by-count":22,"title":["Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy"],"prefix":"10.1097","volume":"27","author":[{"given":"Aaron D.","family":"Brumbaugh","sequence":"first","affiliation":[{"name":"Department of Medicine, Allegheny Health Network, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roshni","family":"Narurkar","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of Oncology, New York Medical College\/Westchester Medical Center, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaushal","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of Oncology, New York Medical College\/Westchester Medical Center, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fanucchi","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of Oncology, New York Medical College\/Westchester Medical Center, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, New York Medical College\/Westchester Medical Center, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/CMR.0000000000000178","article-title":"The conquest of melanoma by immunotherapy.","volume":"25","author":"Lejeune","year":"2015","journal-title":"Melanoma Res"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway.","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40425-016-0166-5","article-title":"Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.","volume":"4","author":"Kanz","year":"2016","journal-title":"J Immunother Cancer"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/j.seminoncol.2015.02.010","article-title":"Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.","volume":"42","author":"Eggermont","year":"2015","journal-title":"Semin Oncol"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma.","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age.","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy.","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/0952-7915(95)80077-8","article-title":"Manipulation of costimulatory signals to enhance antitumor T-cell responses.","volume":"7","author":"Allison","year":"1995","journal-title":"Curr Opin Immunol"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade.","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"e0124059","DOI":"10.1371\/journal.pone.0124059","article-title":"Upregulation of programmed death-1 and its ligand in cardiac injury models: interaction with GADD153.","volume":"10","author":"Baban","year":"2015","journal-title":"PLoS One"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"e000247","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors.","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI35180","article-title":"The anticancer immune response: indispensable for therapeutic success?","volume":"118","author":"Zitvogel","year":"2008","journal-title":"J Clin Invest"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrclinonc.2016.144","article-title":"Circulating and disseminated tumour cells\u2014mechanisms of immune surveillance and escape.","volume":"14","author":"Mohme","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade.","volume":"5","author":"Norwood","year":"2017","journal-title":"J Immunother Cancer"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"e1361097","DOI":"10.1080\/2162402X.2017.1361097","article-title":"Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab.","volume":"6","author":"Reuben","year":"2017","journal-title":"Oncoimmunology"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma.","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/CCO.0000000000000294","article-title":"Rare side-effects of checkpoint inhibitors.","volume":"28","author":"Kourie","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"R27-20230903","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R28-20230903","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R29-20230903","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer.","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"R30-20230903","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"R31-20230903","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"R32-20230903","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma.","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"R33-20230903","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"R34-20230903","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.05.004","article-title":"The heart of the matter: protection of the myocardium from T cells.","volume":"45","author":"Lichtman","year":"2013","journal-title":"J Autoimmun"},{"key":"R35-20230903","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CMR.0000000000000314","article-title":"New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma.","volume":"27","author":"Behling","year":"2017","journal-title":"Melanoma Res"},{"key":"R36-20230903","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors.","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R37-20230903","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/bjc.2017.253","article-title":"Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy.","volume":"117","author":"Tay","year":"2017","journal-title":"Br J Cancer"},{"key":"R38-20230903","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade.","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"R39-20230903","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00262-016-1918-2","article-title":"Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report.","volume":"66","author":"Owonikoko","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"R40-20230903","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1084\/jem.183.6.2533","article-title":"CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.","volume":"183","author":"Krummel","year":"1996","journal-title":"J Exp Med"},{"key":"R41-20230903","doi-asserted-by":"crossref","first-page":"14987","DOI":"10.1073\/pnas.0806075105","article-title":"CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.","volume":"105","author":"Liakou","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R42-20230903","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"R43-20230903","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"R44-20230903","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"R45-20230903","doi-asserted-by":"crossref","first-page":"171","DOI":"10.20892\/j.issn.2095-3941.2016.0015","article-title":"Immuno-oncology combinations: raising the tail of the survival curve.","volume":"13","author":"Harris","year":"2016","journal-title":"Cancer Biol Med"},{"key":"R46-20230903","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/cncr.23086","article-title":"Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.","volume":"110","author":"O\u2019Day","year":"2007","journal-title":"Cancer"},{"key":"R47-20230903","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"R48-20230903","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"R49-20230903","first-page":"794842","article-title":"Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication.","volume":"2015","author":"Yun","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"R50-20230903","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40425-015-0048-2","article-title":"Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome.","volume":"3","author":"Geisler","year":"2015","journal-title":"J Immunother Cancer"},{"key":"R51-20230903","first-page":"1078155218755868","article-title":"Acute autoimmune myocarditis and hepatitis due to ipilimumab monotherapy for malignant melanoma.","volume":"1","author":"Samara","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"R52-20230903","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J Immunother Cancer"},{"key":"R53-20230903","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/1078155216635853","article-title":"Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune monoarthritis induced by ipilimumab use for metastatic melanoma.","volume":"23","author":"Dasanu","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"R54-20230903","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/COC.0b013e318209cda9","article-title":"Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?","volume":"35","author":"Pennock","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"R55-20230903","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/ejhf.806","article-title":"Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia.","volume":"19","author":"Berg","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"R56-20230903","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma.","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"R57-20230903","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"R58-20230903","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity.","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"R59-20230903","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.lungcan.2016.06.025","article-title":"Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung.","volume":"99","author":"Semper","year":"2016","journal-title":"Lung Cancer"},{"key":"R60-20230903","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/CIRCRESAHA.106.147124","article-title":"CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes.","volume":"101","author":"Love","year":"2007","journal-title":"Circ Res"},{"key":"R61-20230903","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"R62-20230903","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","article-title":"PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis.","volume":"188","author":"Tarrio","year":"2012","journal-title":"J Immunol"},{"key":"R63-20230903","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/intimm\/dxq026","article-title":"PD-1 deficiency results in the development of fatal myocarditis in MRL mice.","volume":"22","author":"Wang","year":"2010","journal-title":"Int Immunol"},{"key":"R64-20230903","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation.","volume":"31","author":"Bu","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R65-20230903","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/1556-4029.13633","article-title":"Fatal myocarditis following treatment with the PD-1 inhibitor nivolumab.","volume":"63","author":"Matson","year":"2018","journal-title":"J Forensic Sci"},{"key":"R66-20230903","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ijcard.2016.08.023","article-title":"Pericardial effusion with tamponade physiology induced by nivolumab.","volume":"222","author":"Nesfeder","year":"2016","journal-title":"Int J Cardiol"},{"key":"R67-20230903","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"R68-20230903","doi-asserted-by":"crossref","first-page":"e003514","DOI":"10.1161\/CIRCHEARTFAILURE.116.003514","article-title":"Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab.","volume":"9","author":"Tadokoro","year":"2016","journal-title":"Circ Heart Fail"},{"key":"R69-20230903","doi-asserted-by":"crossref","first-page":"92.e1","DOI":"10.1016\/j.cjca.2017.09.025","article-title":"Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists.","volume":"34","author":"Frigeri","year":"2018","journal-title":"Can J Cardiol"},{"key":"R70-20230903","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.","volume":"3","author":"L\u00e4ubli","year":"2015","journal-title":"J Immunother Cancer"},{"key":"R71-20230903","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"R72-20230903","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"R73-20230903","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R74-20230903","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/jco.2013.31.15_suppl.3061","article-title":"Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models.","volume":"31","author":"Selby","year":"2013","journal-title":"J Clin Oncol"},{"key":"R75-20230903","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.2217\/fon-2016-0037","article-title":"Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma.","volume":"12","author":"Aya","year":"2016","journal-title":"Future Oncol"},{"key":"R76-20230903","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"R77-20230903","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma.","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"R78-20230903","first-page":"1","article-title":"Complete ophthalmoplegia in ipilimumab and nivolumab combination treatment for metastatic melanoma.","volume":"30","author":"Alnabulsi","year":"2018","journal-title":"Orbit"},{"key":"R79-20230903","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/CJI.0000000000000190","article-title":"Life-threatening autoimmune cardiomyopathy reproducibly induced in a patient by checkpoint inhibitor therapy.","volume":"41","author":"Tajmir-Riahi","year":"2018","journal-title":"J Immunother"},{"key":"R80-20230903","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint-blocking antibody side effects.","author":"Postow","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R81-20230903","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40425-016-0185-2","article-title":"Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases.","volume":"4","author":"Kolla","year":"2016","journal-title":"J Immunother Cancer"},{"key":"R82-20230903","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jacc.2018.02.038","article-title":"Cardiac toxicity in patients treated with immune checkpoint inhibitors: it is now time for cardio-immuno-oncology.","volume":"71","author":"Tocchetti","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00045415-201903000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T09:22:18Z","timestamp":1693732938000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-201903000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000217","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}